Revolution Medicines, Inc. (RVMD)
177.65
-22.05
(-11.04%)
USD |
NASDAQ |
Nov 05, 16:00
180.86
+3.21
(+1.81%)
After-Hours: 06:50
Revolution Medicines SG&A Expense (TTM) : 278.15M for Sept. 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 278.15M |
| June 30, 2026 | 330.91M |
| March 31, 2026 | 261.28M |
| December 31, 2025 | 195.04M |
| September 30, 2025 | 156.57M |
| June 30, 2025 | 127.76M |
| March 31, 2025 | 108.90M |
| December 31, 2024 | 96.72M |
| September 30, 2024 | 100.75M |
| June 30, 2024 | 92.31M |
| March 31, 2024 | 85.24M |
| December 31, 2023 | 75.62M |
| September 30, 2023 | 54.29M |
| June 30, 2023 | 49.21M |
| March 31, 2023 | 44.77M |
| December 31, 2022 | 40.58M |
| Date | Value |
|---|---|
| September 30, 2022 | 38.37M |
| June 30, 2022 | 35.72M |
| March 31, 2022 | 32.82M |
| December 31, 2021 | 30.45M |
| September 30, 2021 | 27.58M |
| June 30, 2021 | 25.13M |
| March 31, 2021 | 22.93M |
| December 31, 2020 | 21.43M |
| September 30, 2020 | 19.76M |
| June 30, 2020 | 17.53M |
| March 31, 2020 | 15.16M |
| December 31, 2019 | 12.41M |
| September 30, 2019 | 12.08M |
| June 30, 2019 | 8.976M |
| March 31, 2019 | 6.251M |
| December 31, 2018 | 3.835M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Moderna, Inc. | 965.00M |
| Arrowhead Pharmaceuticals, Inc. | 172.57M |
| Intellia Therapeutics, Inc. | 105.74M |
| Oncolytics Biotech, Inc. | 16.62M |
| Twist Bioscience Corp. | 290.29M |